Related by context. All words. (Click for frequent words.) 68 nonfatal MI 67 prostate cancer CaP 67 atherothrombotic disease 67 CVD mortality 67 β blockers 67 carotid stenosis 67 echocardiographic parameters 66 CR nPR 66 T2 lesions 66 Stent thrombosis 66 artery stenosis 66 nonvertebral fracture 66 morphometric vertebral fractures 66 platelet reactivity 66 LV dysfunction 66 antioxidant supplementation 66 postoperative mortality 66 symptomatic VTE 66 ischemic cardiomyopathy 66 arterial thromboembolic events 65 subclinical atherosclerosis 65 recurrent venous thromboembolism 65 serum urate levels 65 mammographic density 65 familial aggregation 65 colorectal adenoma 65 periprocedural 65 homocysteine concentrations 65 intact parathyroid hormone 65 extrapyramidal symptoms 65 VADT 65 postoperative AF 65 XIENCE V PROMUS Stent 65 thromboembolic 65 Cognitive impairment 65 thromboembolism 65 serum triglycerides 65 OSAHS 64 femoral neck BMD 64 thrombotic complications 64 Subgroup analysis 64 adenoma recurrence 64 meta regression 64 CYP#D# inhibitor 64 noncardiac 64 endoscopic ultrasonography 64 STRIDE PD 64 subclinical hypothyroidism 64 rebleeding 64 perioperative complications 64 definite stent thrombosis 64 thromboembolic events 64 etiologic 64 FDA defined valvulopathy 64 prognostic indicators 64 macrovascular events 64 cerebral microbleeds 64 autonomic dysfunction 64 #F FDG PET 64 antidepressant efficacy 64 abdominal adiposity 64 SLNB 64 atherothrombotic 64 arterial thickening 64 neurocognitive deficits 64 serum folate concentrations 64 thrombotic events 64 substudy 64 recurrent VTE 64 revascularizations 64 gastric cardia 64 elevated LDH 64 perioperative mortality 64 Hb A1C 64 Kaplan Meier analysis 64 atheroma volume 63 nondiabetic patients 63 coronary stenosis 63 ACCOMPLISH 63 nonadherence 63 intima media thickness 63 MMSE score 63 reinfarction 63 hypoperfusion 63 lumbar spine BMD 63 androgen deficiency 63 atherosclerotic vascular disease 63 selenium supplementation 63 multivariate Cox 63 nonfasting triglyceride levels 63 somatoform disorders 63 carotid IMT 63 intracerebral haemorrhage 63 DAPT 63 TEAEs 63 HbA 1c levels 63 dyslipidaemia 63 liver histology 63 T2DM 63 hyperhomocysteinemia 63 subgroup analyzes 63 myocardial fibrosis 63 troponin T 63 tumor histology 63 hyperacute 63 HER2 expression 63 vertebral fracture 63 hepatotoxicity 63 paclitaxel eluting stents 63 antiplatelet drugs 63 Subgroup analyzes 63 antiangiogenic therapy 63 mg BID dose 63 hematopoietic cancers 63 angiographically 63 thromboembolic complications 63 baseline HbA1c 63 NATRECOR ® 63 nonvertebral fractures 63 microvascular complications 63 pCR 63 intravesical therapy 63 inflammatory lesions 63 psychiatric comorbidity 63 Venous thromboembolism 63 prospectively defined 63 BENICAR HCT 63 PSADT 63 ximelagatran 63 recurrent miscarriage 63 elevated CRP 63 sustained virological response 63 SCr 63 postmenopausal hormone 62 hemorrhagic complications 62 pharmacologic treatments 62 lipid lowering therapy 62 thyrotropin levels 62 serum creatinine levels 62 APOE genotype 62 Hepatotoxicity 62 leiomyomas 62 plasma homocysteine 62 composite endpoint 62 KIF6 carriers 62 arterial calcification 62 renal artery stenosis 62 IPAH 62 cobiprostone 62 extensive metabolizers 62 COPD exacerbations 62 Heritability 62 fragility fracture 62 myocardial ischaemia 62 serum homocysteine 62 binary restenosis 62 nonresponders 62 noninferiority 62 platelet inhibition 62 plasma pharmacokinetics 62 beta blocker therapy 62 nonrandomized 62 Randomized trials 62 Cardiotoxicity 62 histological subtype 62 urolithiasis 62 serum uric acid 62 univariate analyzes 62 hip BMD 62 ARCOXIA 62 HbA1C levels 62 affective psychosis 62 NMIBC 62 colorectal liver metastases 62 TT genotype 62 histopathologic findings 62 elevated homocysteine 62 symptomatic intracranial 62 NIHSS score 62 tHcy 62 thyrotropin 62 PROactive study 62 serum retinol 62 biochemical abnormalities 62 cranial irradiation 62 Hypotension 62 carotid plaque 62 ALT elevations 62 interobserver 62 psychiatric comorbidities 62 Bivalirudin 62 pharmacologic intervention 62 #.#/#.# mmHg [001] 62 TOP2A 62 systolic hypertension 62 ASCUS 62 Osteopenia 62 gadolinium enhanced 62 syndromal 62 serum phosphate 62 androgen deprivation 62 albumin excretion rate 62 comorbid disorders 62 endometrial hyperplasia 62 antiarrhythmic drug 62 ACCORD Lipid 62 neurocognitive function 62 rFVIIa 62 prolactin levels 62 silent myocardial ischemia 62 bacterial prostatitis 62 RE LY 62 liver metastasis 62 Renal dysfunction 62 myocardial infarction stroke 62 radical nephrectomy 62 fluvastatin 62 vitamin D inadequacy 62 hyperalgesia 62 valvulopathy 62 antidiabetic drug 62 paroxysmal AF 62 seminomas 62 dose statin therapy 62 cardioprotective effects 62 antithrombotic therapy 62 serum PTH 62 T1DM 62 serum lipid levels 62 perioperative morbidity 62 Orthostatic hypotension 62 ABCB1 62 urothelial carcinoma 62 oncologic outcomes 62 NNT = 62 MADRS score 62 tirofiban 62 Ischemic 62 gadolinium enhancing lesions 62 glomerular filtration 62 biochemical recurrence 62 pT2 61 fondaparinux 61 AST ALT 61 multivariable adjusted 61 hemodilution 61 atherosclerotic progression 61 hematological parameters 61 PCa 61 sotalol 61 Heavy menstrual bleeding 61 cerebrovascular events 61 eplerenone 61 intracranial stenosis 61 androgen suppression 61 chemosensitivity 61 myocardial infarctions 61 QTc intervals 61 GOUT 61 proton MR spectroscopy 61 adnexal mass 61 Univariate analysis 61 ischemic lesions 61 antithrombotic therapies 61 allele frequencies 61 K ras mutations 61 adenoma detection 61 NP CRNs 61 preserved ejection fraction 61 EBUS FNA 61 heterozygotes 61 MDRD 61 ventricular dysfunction 61 platelet activation 61 LUTS 61 neutrophil counts 61 HOMA IR 61 attain statistical significance 61 mitochondrial toxicity 61 radiographic findings 61 nonoperative treatment 61 angiographic outcomes 61 APOE e4 61 impaired glucose metabolism 61 lymphocyte counts 61 locoregional recurrence 61 PAOD 61 white matter hyperintensities 61 angiographic restenosis 61 subtrochanteric 61 CD# expression [001] 61 clinicopathological 61 serum biomarkers 61 clinicopathological features 61 Non Alcoholic Fatty 61 ACUITY trial 61 RE LY trial 61 angiotensin converting enzyme inhibitors 61 LVNC 61 bivariate 61 F FDG PET 61 nonfasting triglycerides 61 pharmacokinetic interactions 61 paricalcitol 61 thromboembolic disease 61 carotid artery stenting CAS 61 residual confounding 61 elevated IOP 61 nomograms 61 prospective multicentre 61 endometrial carcinoma 61 upper gastrointestinal bleeding 61 histologic subtypes 61 tibolone 61 Non inferiority 61 aortic regurgitation 61 microvascular disease 61 nonalcoholic steatohepatitis NASH 61 glycated hemoglobin HbA1c 61 metabolic parameters 61 Kaplan Meier curve 61 fetal malformations 61 HYVET 61 cTnI 61 colorectal adenomas 61 Adjuvant chemotherapy 61 A1c levels 61 rs# [004] 61 Erythropoietic therapies may 61 mycophenolate mofetil 61 lipid lowering agents 61 cerebral vasospasm 61 postoperative atrial fibrillation 61 systolic dysfunction 61 CIMZIA TM certolizumab pegol 61 sUA 61 ASTEROID 61 infarct size 61 oral anticoagulation 61 CSF biomarkers 61 medication nonadherence 61 CTEPH 61 spontaneous preterm delivery 61 QTc prolongation 61 NSTEMI 61 inflammatory biomarkers 61 polyp recurrence 61 HbA 1c 61 postoperative complication 61 fragility fractures 61 cardiovascular mortality 61 antiandrogens 61 confidence intervals CIs 61 nephron sparing surgery 61 atypical hyperplasia 61 lesional 61 cytopenias 61 conjugated equine estrogen 61 dose atorvastatin 61 symptomology 61 comorbid conditions 61 cerebral infarction 61 PHPT 61 postoperative radiotherapy 61 atherogenic dyslipidemia 61 serum estradiol 61 variceal bleeding 61 pleiotropic effects 61 serum BDNF 61 underlying pathophysiology 61 intracranial hemorrhage ICH 61 CK MB 61 intraobserver 61 revascularization procedures 61 univariate 61 nonfatal myocardial infarction MI 61 p = #.# [003] 61 Logistic regression 61 haematologic 61 lipid lowering drugs 61 preoperative chemotherapy 61 liver transplant recipients 61 postmenopausal hormone therapy 61 cardiac repolarization 61 monoclonal gammopathy 61 statistically nonsignificant 61 logistic regression analysis 61 clinicopathologic 61 neurodevelopmental impairment 61 histologic subtype 60 virologic response 60 HRCT 60 contrast induced nephropathy 60 IOP lowering 60 ST Segment Elevation 60 thyroglobulin 60 genotypic resistance 60 NPH insulin 60 Prostatitis 60 hypercalcemia 60 coronary stenoses 60 LT NS# 60 prostate carcinoma 60 lipid lowering medications 60 aldosterone antagonist 60 dopaminergic therapy 60 Nocturia 60 statistical significance p 60 beta carotene supplementation 60 cerebral oxygenation 60 PUFA intake 60 viral kinetics 60 HIV HCV coinfected 60 serum urate 60 nonfatal myocardial infarction 60 noninferior 60 catheter angiography 60 macroalbuminuria 60 RNFL thickness 60 gastric adenocarcinoma 60 hormone therapy estrogen 60 cardiac toxicity 60 contralateral breast cancer 60 subanalysis 60 oral diclofenac 60 intestinal permeability 60 multivariable analysis 60 nonmelanoma skin cancers 60 thrombogenic 60 HER2 overexpression 60 renal toxicity 60 APOC3 60 QTc 60 serum lipid 60 MAGE A3 ASCI 60 creatinine ratio 60 morbidity mortality 60 nodal metastasis 60 Kaplan Meier curves 60 H. pylori eradication 60 dose Iluvien 60 elevated triglyceride levels 60 LDL lowering 60 fatal myocardial infarction 60 imatinib resistance 60 Doxil ® 60 response pCR 60 prospective longitudinal 60 PSA kinetics 60 LDL HDL 60 nmol liter 60 albumin excretion 60 sonographically 60 meta analytic 60 lactate dehydrogenase LDH 60 N. Engl 60 aetiology 60 RE LY ® 60 unmeasured confounding 60 cardiac dysfunction 60 differential gene expression 60 cytoreductive nephrectomy 60 everolimus eluting stents 60 nephrotoxicity 60 cortical atrophy 60 serum calcium levels 60 prognostic significance 60 HeFH 60 Papillary 60 BPS IC 60 Proteinuria 60 sirolimus eluting stents 60 ± SEM 60 node metastases 60 prognostic variables 60 atypical antipsychotic medications 60 mTOR inhibitors 60 rs# [002] 60 LVEF 60 flutamide 60 KRAS status 60 metabolic disturbances 60 interobserver reliability 60 ALB # 60 antiplatelet therapies 60 #OHD 60 ß blockers 60 antiplatelet medications 60 pretest probability 60 multivariable Cox 60 invasive ductal 60 PSA nadir 60 ATACAND 60 atherosclerotic renal artery stenosis 60 agomelatine 60 generalisability 60 C1 INH deficiency 60 prespecified secondary 60 radiographic progression 60 Genetic variants 60 CP CPPS 60 recurrent ischemia 60 hematologic toxicity 60 Carvedilol 60 hormone receptor negative 60 postoperative delirium 60 Observational studies 60 multivariate adjustment 60 logistic regression analyzes 60 microvessel 60 CaPre TM 60 Thal Dex 60 venous thromboembolic disease 60 chronicity 60 μmol L 60 amisulpride 60 metastatic neuroendocrine tumors 60 glycated hemoglobin 60 corrected QT interval 60 baseline LDH 60 myocardial ischemia 60 relapsed MM 60 idraparinux 60 poor metabolizers 60 microalbuminuria 60 recurrent GBM 60 recurrent DVT 60 gastrointestinal GI bleeding 60 Afib 60 oocytes retrieved 60 mL/min/#.# m 2 60 HMG CoA reductase inhibitors 60 adrenalectomy 60 acute cholecystitis 60 ticagrelor 60 oxcarbazepine 60 baseline serum creatinine 60 Crohn Disease Activity 60 ventricular myocardium 60 tolvaptan 60 malabsorptive 60 DHEA supplementation 60 infarctions 60 Atherosclerotic 60 HGPIN 60 generalizability 60 Serious adverse reactions 60 cardiovascular morbidity 60 Comorbidity 60 Operative mortality 60 antidiabetic medication 60 prostate cancer PCa 60 osteosarcomas 60 plasma cortisol 59 Lenalidomide 59 diabetes mellitus DM 59 polypoid 59 apo B apo AI 59 bone scintigraphy 59 glycosylated hemoglobin HbA1c 59 ipsilateral stroke 59 gene polymorphism 59 intensive statin therapy 59 nondiabetics 59 chlorthalidone 59 antithrombotics 59 magnesium intake 59 NIH CPSI 59 aminotransferase 59 chronic periodontitis 59 microbleeds 59 sirolimus stent 59 Primary endpoints 59 myocardial infarction MI 59 prognostic indicator 59 radiochemotherapy 59 ranolazine 59 pretreatment serum 59 HF hospitalization 59 neurologic complications 59 cardiovascular hospitalization 59 logistic regression model 59 #.#mg/dL 59 fasting triglycerides 59 nicardipine 59 oesophageal adenocarcinoma 59 thiopurine 59 afterload 59 leukocyte count 59 conventional angiography 59 neoadjuvant 59 venous thromboembolic events 59 myocardial infarctions MIs 59 oxycodone CR 59 visceral adiposity 59 stent thromboses 59 multimodality therapy 59 Thalomid ® 59 MACCE 59 abciximab 59 macrovascular 59 lymphadenectomy 59 transferrin saturation 59 virological response 59 resuscitated cardiac arrest 59 SSc 59 Leydig cell 59 colorectal neoplasms 59 CYP#D# genotype 59 serum parathyroid hormone 59 confidence interval #.#-#.# 59 lipoprotein Lp 59 dose dependently 59 advanced adenoma 59 apolipoprotein B 59 transaminase levels 59 atorvastatin #mg 59 PNH patients 59 antiphospholipid antibodies 59 Heterogeneity 59 unfractionated heparin UFH 59 vulvovaginal atrophy 59 diastolic BP 59 Suicidal ideation 59 neurodevelopmental outcome 59 paroxetine sertraline 59 plasma renin activity 59 prostate carcinogenesis 59 glycated hemoglobin levels 59 Symptom severity 59 ivabradine 59 probable stent thrombosis 59 repeat revascularization 59 multivariate analyzes 59 MGUS 59 hyperintense lesions 59 thyroid carcinoma 59 MGd 59 MAXALT 59 clomipramine 59 atherogenic 59 aldosterone antagonists 59 heritable variation 59 arteriography 59 triacylglycerol concentrations 59 advanced adenomas 59 myocardial revascularization 59 aminotransferases 59 venlafaxine Effexor 59 CETP inhibition 59 NSTE ACS 59 skeletal metastases 59 autoantibody levels 59 prospectively stratified 59 AA Amyloidosis 59 CLINICAL PHARMACOLOGY 59 preoperative PSA 59 postdischarge 59 WOMAC pain 59 atrophic gastritis 59 cirrhotic patients 59 Trandolapril 59 resynchronization therapy 59 paroxetine Paxil 59 adjuvant therapies 59 alexithymia 59 thrombophilia 59 hypovitaminosis D 59 liposomal amphotericin B 59 complete cytogenetic response 59 variant angina 59 antiandrogen 59 Rating Scale BPRS 59 NNRTI resistance 59 CHD mortality 59 convergent validity 59 variceal 59 DAS# remission 59 natriuretic peptides 59 NIHSS 59 intravitreal injections 59 CsA 59 p = .# [002] 59 CHADS 59 XIENCE V demonstrated 59 neuroregenerative 59 nondepressed 59 mammographic breast density 59 hyperoxaluria 59 coronary calcification 59 ventricular tachyarrhythmia 59 subclinical hyperthyroidism 59 TZDs 59 postprandial glycemia 59 bivariate analyzes 59 umol L 59 intra ocular pressure 59 interindividual variability 59 LHRH agonists 59 serum calcium 59 invasive aspergillosis 59 postoperative morbidity 59 familial clustering 59 pharmacokinetic equivalence 59 carotid plaques 59 conventional antipsychotics 59 ALT elevation 59 phytoestrogen intake 59 nonselective NSAIDs 59 mucinous 59 non valvular atrial 59 adjuvant trastuzumab 59 glycaemia 59 hormone therapy HT 59 GnRH agonists 59 ibandronate 59 irbesartan 59 posaconazole 59 apo B 59 hemoglobin A1c levels 59 DES implantation 59 lung metastasis 59 pulmonary toxicity 59 HBeAg negative 59 choroidal neovascularization 59 TNF antagonist 59 blood Phe levels 59 pathophysiologic 59 rs# [001] 59 CYPHER ® 59 mutated K ras 59 tertiles 59 splenectomized patients 59 HbA 1C 59 Bosentan 59 pathophysiological mechanisms 59 hepatic cirrhosis 59 atypical fractures 59 conditional logistic regression 59 ARB telmisartan 59 BRCA2 mutation carriers 59 P = .# 59 systemic toxicity 59 scintigraphic 59 comorbidity 59 ELBW infants 59 cilostazol 59 Subarachnoid hemorrhage 59 Diabetic nephropathy 59 postmenopausal hormones 59 Helicobacter pylori infection 59 nodal metastases 59 nonfatal stroke 59 CYPHER R Sirolimus eluting 59 comorbid anxiety 59 cardiac troponin T 59 MERLIN TIMI 59 lowest tertile 59 Ranolazine 59 ADAS Cog 59 lipid abnormalities 59 haematological toxicity 59 EGFR mutation status 59 vaginal hysterectomy 59 CORE OM 59 Hyperlipidemia 59 treat NNT 59 denervation 59 predisposing factor 59 prolonged QT interval 59 SUVmax 59 estrogen progestin therapy 59 neointimal hyperplasia 59 prodromal symptoms 59 Prehypertension 59 anastomotic leak 59 microvessel density 59 hepatocellular carcinomas 59 nonischemic 59 gene polymorphisms 59 thrombolytic agents 59 SVR# 59 Histologic 59 postprocedure 59 transurethral resection 59 hippocampal atrophy 59 thienopyridines 59 aspirin clopidogrel 59 eculizumab therapy 59 thromboprophylaxis 59 QT prolongation 59 urine cytology 59 Comorbidities 59 cardioembolic stroke 59 antimuscarinic 59 antihypertensive therapy 59 osteopenic 59 elevated creatinine 59 divalproex sodium 59 PPAR gamma agonists 59 rosuvastatin Crestor 59 patients undergoing CABG 59 advanced neoplasia 59 undergoing CABG 59 TRANSFORMS 59 Aortic stenosis 59 HbF 59 bosentan 59 immunomodulation 59 membranous nephropathy 59 parous women 59 genetic polymorphisms 59 uricase 59 myopathy rhabdomyolysis 59 Ophena TM 59 Ishak fibrosis score 59 Multiple linear regression 59 cryptogenic 59 serum concentrations 59 obese postmenopausal 59 corticosteroid dose 59 pharmacodynamic parameters 58 Bonferroni correction 58 antibody titer 58 GBA mutations 58 Multivariate analysis 58 SGAs 58 haemorrhagic stroke 58 intraoperative complications 58 citalopram Celexa 58 thrombus aspiration 58 labetalol 58 FASLODEX 58 antiarrhythmic 58 LVSD 58 spirometric 58 Multiple logistic regression 58 lipid elevations 58 Febrile neutropenia 58 SNP rs# [002] 58 electrophysiologic 58 MMSE scores 58 conventional coronary angiography 58 primary aldosteronism 58 antigen PSA levels 58 POAG 58 metabolite concentrations 58 Hashimoto thyroiditis 58 serum PSA 58 EFFEXOR XR 58 cervicitis 58 Randomized controlled 58 Renal Cell Carcinoma RCC 58 Haptoglobin 58 BRCA mutation carriers 58 reflux esophagitis 58 antiangiogenic agents 58 treatment emergent AEs 58 ertapenem 58 neutropaenia 58 Suicidality 58 hsCRP 58 digital subtraction angiography 58 nonpharmacologic interventions 58 SGPT 58 Calcium intake 58 FDG uptake 58 virologic failure 58 SRBD 58 plasma folate 58 incidentalomas 58 ischemia driven 58 carotid intima media 58 eosinophil count 58 Fibrates 58 steatohepatitis 58 microvascular dysfunction 58 simvastatin ezetimibe 58 μg liter 58 serum lipids 58 chlamydial infection 58 clinically meaningful differences 58 rCBF 58 SYNTAX trial 58 VaD 58 acetabular dysplasia 58 pioglitazone Actos 58 NATRECOR R 58 APTIVUS r 58 hypercalciuria 58 salivary flow 58 Pioglitazone 58 J Am Coll 58 docetaxel pretreated 58 Endarterectomy 58 adjunctive placebo 58 androgen depletion 58 clinically insignificant 58 plus medroxyprogesterone acetate 58 perimenopausal women 58 liver transaminases 58 schizophrenia CIAS 58 cytogenetic abnormalities 58 somatic symptoms 58 foveal thickness 58 nonsignificant 58 Pharmacokinetic studies 58 TRITON TIMI 58 Statin therapy 58 secondary efficacy endpoint 58 ascertainment bias 58 mammographically 58 carotid revascularization 58 HSCT 58 chemoradiotherapy 58 knee osteoarthritis OA 58 osteoporotic vertebral compression fractures 58 urinary N telopeptide 58 desvenlafaxine succinate 58 plasma glucose concentration 58 thiazide diuretics 58 ventricular remodeling 58 riociguat 58 lipid parameters 58 Teriparatide 58 tricyclic antidepressant 58 hyperglycaemia 58 Thiazolidinediones 58 thrombocytopenic 58 CIN2 + 58 teriparatide 58 chronic prostatitis 58 Flu Cy 58 homozygotes 58 5 HT2C receptor 58 PRADAXA 58 deferiprone 58 tipranavir 58 Index CDAI 58 hepatectomy 58 triglyceride concentrations 58 peri procedural 58 HBeAg seroconversion 58 esophagogastric 58 pharmacological therapies 58 femoral neck fracture 58 primidone 58 overactive bladder symptoms 58 dysfunction LVSD 58 recurrent ischemic stroke 58 anemia hemoglobin 58 adjuvant systemic 58 neurologic progression 58 GI toxicity 58 creatine kinase MB 58 cardioprotective effect 58 cytologic 58 pulmonary artery banding 58 myocardial reperfusion 58 renal fibrosis 58 antiphospholipid syndrome 58 myocardial infarction 58 vidofludimus 58 myeloperoxidase 58 Ivabradine 58 pharmacologic approaches 58 HbA1c levels 58 TMP SMX 58 hepatocellular 58 metabolic abnormalities 58 sulphonylureas 58 clinico pathological 58 Unstable Angina 58 schizotypal traits 58 % Confidence Interval 58 elevated troponin 58 Selective serotonin reuptake inhibitors 58 Y BOCS 58 molecularly defined 58 NIDDM 58 epithelial tumors 58 radical prostatectomy RP 58 T1a 58 corneal thickness 58 antiangiogenic agent 58 pharmacodynamic PD 58 asymptomatic carotid stenosis 58 rosuvastatin #mg 58 glitazones 58 noncardiovascular mortality 58 alkalosis 58 lobular breast cancer 58 HAM D# scores 58 Lp PLA 2 58 thiazide 58 Intervention Effectiveness CATIE 58 urinary calcium 58 euthymic patients 58 nonalcoholic steatohepatitis